Pre-employment drug and alcohol testing in Australia is lawful when conducted after a conditional job offer, applied consistently across candidates for the same role, and grounded in documented inherent requirements. Testing must follow AS 4308:2023 (urine) or AS 4760:2019 (oral fluid) end-to-end — including NATA-accredited laboratory analysis and MRO review — before any result is communicated to an employer.
Why the legal framework matters more than the test result
A positive drug screen that cannot be defended in a discrimination complaint is worse than no test at all. It creates liability without providing protection. And yet the number of employers who commission pre-employment drug testing without following AS 4308:2023 or without ensuring MRO review is, conservatively, still significant across Australian industry.
The Disability Discrimination Act 1992 (Cth) is the starting point. Section 21A permits employers to impose requirements on candidates — including health-related ones — provided those requirements reflect genuine inherent requirements of the job. A pre-employment drug test for a safety-critical role is defensible on this basis. A drug test for a sedentary administrative role with no safety-critical function is much harder to defend.
The model Work Health and Safety Act 2011 adds the second layer. The primary duty of care in section 19 requires an employer to ensure, so far as is reasonably practicable, the health and safety of workers. For roles in mining, heavy transport, plant operation, emergency response, or construction — where a worker under the influence of drugs or alcohol directly creates serious risk of injury or death — pre-employment testing is one of the reasonably practicable controls.
The sequencing rule is non-negotiable: the conditional offer must be made before any health information — including a drug test — is collected. Collecting a drug screen before an offer has been made inverts the legal framework and removes the inherent-requirements justification entirely.
AS 4308:2023 and AS 4760:2019 — what each standard actually requires
Two Australian Standards govern workplace drug testing. AS 4308:2023 covers urine specimen collection and the on-site testing of drugs of abuse. AS 4760:2019 covers oral fluid collection and testing. For pre-employment purposes, both are acceptable — with urine being the predominant method for laboratory-confirmed testing and oral fluid being increasingly used for its observed-collection advantage and shorter detection window.
Both standards impose requirements across the entire testing process — not just the collection event:
| Requirement | AS 4308:2023 (Urine) | AS 4760:2019 (Oral Fluid) |
|---|---|---|
| Collector | Trained, authorised, documented competency | Trained, authorised, documented competency |
| Collection | Observed or unobserved per policy; tamper-evident sealing | Observed collection only; direct oral collection |
| Chain of custody | End-to-end CoC form; specimen must not leave CoC at any point | End-to-end CoC form; same requirements |
| Laboratory | NATA-accredited laboratory; confirmation at specific cut-offs | NATA-accredited laboratory; GC-MS/MS confirmation |
| MRO review | Required for all non-negative results before employer notification | Required for all non-negative results before employer notification |
| Substances tested | Cannabis, opioids, amphetamines, cocaine metabolites, benzodiazepines (minimum) | Cannabis, opioids, amphetamines, cocaine metabolites (minimum) |
| Detection window | Days to weeks (cannabis metabolite up to 30+ days in heavy users) | Hours to 1–2 days — reflects recent use |
A test result communicated to an employer without MRO review is non-compliant and cannot support an employment decision. The MRO exists to review whether a non-negative result has a legitimate medical explanation — a valid prescription for a tested substance is the most common scenario. Without MRO review, a candidate on prescribed opioids for a chronic pain condition could have their conditional offer withdrawn based on a result that would have been cleared as legitimate.
The MRO process — what happens between the lab result and your inbox
The Medical Review Officer is a medical practitioner with specific training in substance testing and MRO practice. Their role is to receive the laboratory result, contact the donor (the candidate) to determine whether there is a legitimate medical explanation, and issue a final result — either negative (if a legitimate explanation was accepted) or confirmed non-negative — to the testing facility for communication to the employer.
The step-by-step process after a laboratory non-negative:
- 1Laboratory notifies MRO of non-negative result, including substance class and concentration.
- 2MRO contacts the donor directly — not via the employer — to request disclosure of any prescription medications or medical conditions relevant to the result.
- 3Donor provides documentation (prescription records, treating clinician contact) within the timeframe specified.
- 4MRO reviews the documentation, contacts the prescriber if necessary, and determines whether the prescription was valid and consistent with the detected result.
- 5If a legitimate explanation is accepted: MRO issues a negative result. The employer receives a negative — the substance involved is not disclosed.
- 6If no legitimate explanation: MRO issues a confirmed non-negative result. The substance class and a brief MRO determination statement are communicated to the employer (not the concentration).
- 7Employer makes the employment decision in accordance with the D&A policy for that role.
The employer is not involved in the MRO review process. The clinical dialogue is between the MRO and the donor. This separation protects both the candidate's privacy and the employer's compliance position.
Cannabis testing — the detection window problem
Cannabis is the substance that generates the most questions from employers and the most complaints from candidates. The issue is detection window. Urine testing for cannabis detects the THC-COOH metabolite, which can remain detectable for 3–4 days in occasional users and up to 30 or more days in heavy, chronic users — long after any pharmacological effect has ceased.
This means a pre-employment urine cannabis positive does not establish that the candidate was impaired on the day of testing, or that they would be impaired if they commenced work. What it establishes is that they used cannabis at some point within the detection window for their level of use.
For employers making employment decisions on this basis, the policy must be explicit. The most defensible position for safety-critical roles is a zero-tolerance pre-employment policy: a confirmed non-negative cannabis result means the conditional offer is withdrawn, regardless of when use occurred. The policy must be applied consistently — a confirmed positive for one candidate means the same outcome for all candidates for that role.
Oral fluid testing using AS 4760:2019 has a much shorter cannabis detection window — typically 4–12 hours — which more closely reflects recent use. Employers seeking a test that is more tightly correlated with recent impairment may specify oral fluid. The trade-off is reduced sensitivity for intermittent users who used more than a day before testing.
Policy design — five things that make a D&A policy defensible in practice
The technical testing process is only half the picture. The other half is the policy that governs what happens when a result comes back. A policy that is silent on key decision points creates inconsistency, and inconsistency creates discrimination exposure. These five elements are what distinguish a defensible pre-employment D&A policy from a liability:
Which roles are tested and why
The policy must specify the role categories covered by pre-employment D&A testing and the basis for their inclusion. For safety-critical roles, the basis is the IROJ documentation of safety-critical functions. For roles covered by principal contractor or enterprise agreement requirements, the basis is the contractual or EA obligation. For other roles, the basis must be documented or the testing is indefensible.
The standard used and who conducts testing
AS 4308:2023 or AS 4760:2019, as applicable. The policy should name the standard, specify that testing is conducted by trained, authorised collectors, that laboratory analysis is performed by a NATA-accredited facility, and that MRO review precedes any notification to the employer.
The outcome — confirmed non-negative means what, exactly
The policy must state the consequence of a confirmed non-negative pre-employment result. "Conditional offer withdrawal" is the most common outcome for safety-critical roles. Where a different consequence is possible, the criteria for that decision must be specified — vague language like "may result in withdrawal" creates inconsistency and challenge risk.
Retest entitlement and conditions
The policy must state whether a retest is offered, the abstinence period before retesting, and whether a negative retest result makes the candidate eligible for the same role or only for future vacancies. If retests are offered for some roles and not others, the criteria for that differentiation must be documented.
Privacy and records
The fitness outcome (negative or confirmed non-negative) is provided to the employer. The clinical details (substance, concentration, MRO determination) are retained by the occupational health provider. The policy must reference the Privacy Act 1988 (Cth) obligations and specify that test results are health information subject to the Australian Privacy Principles.
Enterprise agreements and principal contractor requirements — the compliance layer most employers miss
For many organisations in construction, mining, and resources, the pre-employment D&A testing obligation does not come primarily from their own policy — it comes from their principal contractor or from the enterprise agreement that covers the relevant workforce.
A principal contractor requirement typically specifies: the standard to be used (AS 4308:2023 or AS 4760:2019), the required laboratory confirmation, the cut-off concentrations that apply, the substances to be tested, the MRO requirement, and the documentation that must be available on site or on request. Where a principal contractor requirement specifies these elements, the employer must ensure their testing program meets all of them — not just some.
Enterprise agreements may impose obligations at a higher level than the employer's own policy — for example, specifying a broader panel of tested substances or requiring oral fluid rather than urine. Where an enterprise agreement is in place, the D&A policy must be reviewed against it to ensure consistency. A pre-employment test result that was collected in compliance with the employer's policy but not the EA standard may not satisfy the EA obligation.
Frequently asked questions
Is pre-employment drug and alcohol testing legal in Australia?
Yes. Pre-employment drug and alcohol testing is lawful in Australia provided it is conducted after a conditional offer of employment, applied consistently to all candidates for the same role, and grounded in documented inherent requirements of the job (IROJ). The Disability Discrimination Act 1992 (Cth) permits employers to require candidates to meet genuine inherent requirements of a role. For safety-critical roles — particularly in mining, transport, construction, and resources — the employer's obligation under the model Work Health and Safety Act 2011 to eliminate or minimise risk to workers provides additional legal basis. Testing must follow AS 4308:2023 (urine) or AS 4760:2019 (oral fluid) to be defensible.
What do AS 4308:2023 and AS 4760:2019 require for pre-employment testing?
AS 4308:2023 governs urine collection and testing for drugs of abuse; AS 4760:2019 governs oral fluid testing. Both standards require: (1) trained and authorised collector performing the collection; (2) strict chain-of-custody documentation from collection to laboratory receipt; (3) NATA-accredited laboratory analysis at mandated cut-off concentrations; (4) a Medical Review Officer (MRO) to review all non-negative results before any outcome is communicated to the employer. A result communicated to an employer without MRO review is not compliant with either standard and cannot be used as the basis of an employment decision.
What does a confirmed non-negative pre-employment drug test mean for the employment decision?
A confirmed non-negative result means the laboratory has detected the presence of a substance (or metabolite) above the AS 4308:2023 or AS 4760:2019 cut-off concentration, after MRO review has excluded legitimate medical explanations. It does NOT establish impairment at the time of the test. The employment decision must be made in accordance with the employer's drug and alcohol policy for that role. For most safety-critical roles, a confirmed non-negative following MRO review supports withdrawal of the conditional offer — but the policy must say so explicitly, and the decision must be consistent across all candidates.
Can an employer ask a candidate to retest after a non-negative pre-employment result?
An employer can offer a retest, but is not obliged to. For pre-employment testing, many employers treat a confirmed non-negative as a withdrawal of the conditional offer without offering a retest — particularly for safety-critical roles. Where a retest is offered, a minimum abstinence period (typically 30–90 days) is usually specified. The employer's drug and alcohol policy should state the retest entitlement (if any), the abstinence period, and whether a candidate who retests negative is eligible for re-engagement. Inconsistent application of the retest provision creates discrimination risk.
Does pre-employment drug testing apply to cannabis, prescription medications, and alcohol?
AS 4308:2023 urine testing covers: cannabis (THC metabolite), opioids, amphetamines/methamphetamine, cocaine metabolites, and benzodiazepines as a minimum panel — with additional substances tested where specified. A positive cannabis result can occur days to weeks after last use in regular users, reflecting metabolite excretion, not current impairment. Prescription medications that produce positive results are reviewed by the MRO; a valid prescription for therapeutic use is typically a legitimate medical explanation. Alcohol testing under AS 4760:2019 oral fluid measures ethanol directly and reflects recent use only. Pre-employment alcohol testing is included where the role warrants it and the employer's policy covers it.
What are the privacy obligations for pre-employment drug and alcohol test results?
Drug and alcohol test results are health information under the Privacy Act 1988 (Cth) and are subject to the Australian Privacy Principles. The collection must be for a specified, lawful purpose (pre-employment fitness assessment). The result communicated to the employer must be a fitness outcome only — the clinical details (substances detected, concentrations) must be held by the occupational health provider, not provided to the employer unless the candidate consents or a specific legal requirement applies. Records must be retained securely for a minimum of 7 years and destroyed in accordance with the employer's records management policy.
Related articles
Drug & Alcohol Testing
OccuSpan's end-to-end D&A testing program — pre-employment, random, post-incident, and for-cause.
Pre-Employment Screening
How to build a defensible PES process that covers every role category across multiple sites.
Pre-Employment Medical Assessment
What a pre-employment medical actually involves, and when each component is justified.
Fitness for Work Assessment
Assessing ongoing fitness for work — when and how to conduct a review without creating discrimination exposure.
Drug & Alcohol Testing
Pre-employment testing that holds up
OccuSpan's D&A testing program is built on AS 4308:2023 and AS 4760:2019, with NATA-accredited laboratory processing, qualified MRO review, and audit-ready documentation — for employers who need a testing program they can actually defend.
View drug & alcohol testing servicesThis article is general guidance only and does not constitute legal advice. Employers should ensure their drug and alcohol testing program and related policies are reviewed by qualified legal and occupational health practitioners. Relevant instruments include the Disability Discrimination Act 1992 (Cth), model Work Health and Safety Act 2011, Privacy Act 1988 (Cth), AS 4308:2023, and AS 4760:2019. Enterprise agreement and principal contractor requirements may impose additional obligations. OccuSpan is a service of Work Healthy Australia Pty Ltd. ABN 62 602 462 885.